Treatment Information

Back

Breast Cancer treatment details. Chemotherapy.

Baylor-Sammons Cancer Center, Dallas, Texas, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Dallas, Texas
Treatments:ChemotherapyHospital:Baylor-Sammons Cancer Center
Drugs:Journal:Link
Date:Jun 2002

Description:

Patients: This Phase III study involved 511 women with metastatic breast cancer or breast cancer that was unresectable and locally advanced. Patients were divided into two groups: Group A contained 255 patients, and Group B contained 256 patients.

Treatment: The treatment for patients in group A consisted of two chemotherapy drugs – docetaxel (taxotere) and capecitabine (xeloda). The treatment for patients in group B consisted of only docetaxel.

Toxicity: In Group A, one patient died of entercolitis which was “probably” related to the treatment. Another patient died of sepsis which was “possibly related” to the treatment. A third patient died of pulmonary edema that was “probably related” to the treatment. And a fourth patient died from hepatic coma that was “possibly” related to the treatment. In addition, grade 3-4 toxicities included: neutropenic fever, stomatitis, diarrhea, nausea, hand-foot syndrome, alopecia, and fatigue/asthenia.

Results: Median survival for patients in Group A was 14.5 months.

Support: This research was supported by F. Hoffman-La Roche. In addition, some of the study’s authors have received monetary compensation (over $2,000/year) from F. Hoffman-La Roche or Aventis, or both. Aventis markets taxotere and Roche markets xeloda.

Correspondence: Joyce O'Shaughnessy, MD





Back